| Stereochemistry | RACEMIC |
| Molecular Formula | C19H18ClFN2O3 |
| Molecular Weight | 376.809 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN1C2=CC=C(Cl)C=C2C3(OCCN3CC1=O)C4=CC=CC=C4F
InChI
InChIKey=WMFSSTNVXWNLKI-UHFFFAOYSA-N
InChI=1S/C19H18ClFN2O3/c20-13-5-6-17-15(11-13)19(14-3-1-2-4-16(14)21)22(8-10-26-19)12-18(25)23(17)7-9-24/h1-6,11,24H,7-10,12H2
| Molecular Formula | C19H18ClFN2O3 |
| Molecular Weight | 376.809 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Flutazolam is a benzodiazepine derivative developed in Japan by Mitsui. The drug is marketed under the name Coreminal and used for the treatment of gastrointestinal disorders. The mechanism of flutazolam action is due to activation of GABA-A receptors as it has affinity to the benzodiazepine binding sites.
CNS Activity
Originator
Approval Year
PubMed
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
Showing 1 to 2 of 2 entries
